Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
03 Jan 2024
03 Jan 2024
Historique:
received:
28
06
2023
accepted:
13
11
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
aheadofprint
Résumé
Melanoma disease patterns vary with patient age. To evaluate sentinel lymph node biopsy (SLNB) in managing melanoma at differing patient ages. Online prediction tools were applied to compare SLNB positivity (SLNB Regardless of tumour thickness, predicted SLNB If 1000 20-year-olds with a 0.4 mm thickness non-ulcerated melanoma underwent SLNB, 100 would likely be positive. If all 100 were to be offered adjuvant drug therapy (ADT), fewer than three more melanoma deaths in those 1000 patients would be avoided. In total, 97 patients would have received medication they may never have needed. If 1000 80-year-olds with a 3 mm thickness non-ulcerated melanoma underwent SLNB, only 40 would likely be positive. In total, 274 patients would be predicted to die of melanoma, 245 being SLNB negative and 29 SLNB The authors relied on published risk data. SLNB has poor specificity at predicting mortality in young melanoma patients and poor sensitivity in older patients. SLNB is not indicated in managing cutaneous melanoma for patients under 40 or over 60 years of age. Many such patients could be managed with wide local excision alone in their clinician's office-based practice. For all cutaneous melanoma patients at all ages, linking ADT to BAUSSS biomarker, (an algorithm of Breslow thickness, age, ulceration, subtype, sex and Site) rather than SLNB
Sections du résumé
BACKGROUND
BACKGROUND
Melanoma disease patterns vary with patient age.
AIM
OBJECTIVE
To evaluate sentinel lymph node biopsy (SLNB) in managing melanoma at differing patient ages.
METHODS
METHODS
Online prediction tools were applied to compare SLNB positivity (SLNB
RESULTS
RESULTS
Regardless of tumour thickness, predicted SLNB
DISCUSSION
CONCLUSIONS
If 1000 20-year-olds with a 0.4 mm thickness non-ulcerated melanoma underwent SLNB, 100 would likely be positive. If all 100 were to be offered adjuvant drug therapy (ADT), fewer than three more melanoma deaths in those 1000 patients would be avoided. In total, 97 patients would have received medication they may never have needed. If 1000 80-year-olds with a 3 mm thickness non-ulcerated melanoma underwent SLNB, only 40 would likely be positive. In total, 274 patients would be predicted to die of melanoma, 245 being SLNB negative and 29 SLNB
LIMITATIONS
CONCLUSIONS
The authors relied on published risk data.
CONCLUSION
CONCLUSIONS
SLNB has poor specificity at predicting mortality in young melanoma patients and poor sensitivity in older patients. SLNB is not indicated in managing cutaneous melanoma for patients under 40 or over 60 years of age. Many such patients could be managed with wide local excision alone in their clinician's office-based practice. For all cutaneous melanoma patients at all ages, linking ADT to BAUSSS biomarker, (an algorithm of Breslow thickness, age, ulceration, subtype, sex and Site) rather than SLNB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 European Academy of Dermatology and Venereology.
Références
Osmani S, Chao Z, Barnhill R, Berwick M. Not every age is created equal: risk factors for melanoma differ by age. Int J Dermatol. 2022;61(2):e74-e76.
Olsen CM. Global trends in melanoma mortality differ by sex and age. Br J Dermatol. 2020;183(6):985-986.
Gutierrez-Gonzalez E, Lopez-Abente G, Aragones N, Pollan M, Pastor-Barriuso R, Sanchez MJ, et al. Trends in mortality from cutaneous malignant melanoma in Spain (1982-2016): sex-specific age-cohort-period effects. J Eur Acad Dermatol Venereol. 2019;33(8):1522-1528.
Tas F, Erturk K. Patient age and cutaneous malignant melanoma: elderly patients are likely to have more aggressive histological features and poorer survival. Mol Clin Oncol. 2017;7(6):1083-1088.
Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112(8):1795-1804.
Sinnamon AJ, Neuwirth MG, Yalamanchi P, Gimotty P, Elder DE, Xu X, et al. Association between patient age and lymph node positivity in thin melanoma. JAMA Dermatol. 2017;153(9):866-873.
Hanna AN, Sinnamon AJ, Roses RE, Kelz RR, Elder DE, Xu X, et al. Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00 mm): a National Cancer Database study. J Am Acad Dermatol. 2019;80(2):433-440.
Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014;21(4):1075-1081.
Page AJ, Li A, Hestley A, Murray D, Carlson GW, Delman KA. Increasing age is associated with worse prognostic factors and increased distant recurrences despite fewer sentinel lymph node positives in melanoma. Int J Surg Oncol. 2012;2012:456987.
Cavanaugh-Hussey MW, Mu EW, Kang S, Balch CM, Wang T. Older age is associated with a higher incidence of melanoma death but a lower incidence of sentinel lymph node metastasis in the SEER databases (2003-2011). Ann Surg Oncol. 2015;22(7):2120-2126.
Zagarella S. Sentinel lymph node biopsy still provides No benefits for patients with melanoma. Am J Dermatopathol. 2020;42(7):481-483.
El Sharouni MA, Stodell MD, Ahmed T, Suijkerbuijk KPM, Cust AE, Witkamp AJ, et al. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Ann Oncol. 2021;32(3):375-383.
Dixon AJ, Steinman HK, Kyrgidis A, Smith H, Sladden M, Zouboulis C, et al. Improved methodology in determining melanoma mortality and selecting patients for immunotherapy. J Eur Acad Dermatol Venereol. 2023;37(7):e843-e845.
Lo SN, Ma J, Scolyer RA, Haydu LE, Stretch JR, Saw RPM, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute Australia nomogram. J Clin Oncol. 2020;38(24):2719-2727.
Zabor EC, Coit D, Gershenwald JE, McMasters KM, Michaelson JS, Stromberg AJ, et al. Variability in predictions from online tools: a demonstration using internet-based melanoma predictors. Ann Surg Oncol. 2018;25(8):2172-2177.
Dixon A, Steinman HK, Kyrgidis A, Smith H, Sladden M, Zouboulis C, et al. Online prediction tools for melanoma survival: a comparison. J Eur Acad Dermatol Venereol. 2023;37:1999-2003.
Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, et al. Prognosis of patients with primary melanoma stage I and II according to American joint committee on cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol. 2022;40(32):3741-3749.
Marchetti MA, Dusza SW, Bartlett EK. Utility of a model for predicting the risk of sentinel lymph node metastasis in patients with cutaneous melanoma. JAMA Dermatol. 2022;158(6):680-683.
Woods JF, De Marchi JA, Lowery AJ, Hill AD. Validation of a nomogram predicting sentinel lymph node status in melanoma in an Irish population. Ir J Med Sci. 2015;184(4):769-773.
Kretschmer L, Hilgers R, Mohrle M, Balda BR, Breuninger H, Konz B, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004;40(2):212-218.
Thomas JM. Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol. 2005;23(36):9443-9444.
Rosenberg SA. Why perform sentinel-lymph-node biopsy in patients with melanoma? Nat Clin Pract Oncol. 2008;5(1):1.
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599-609.
Sladden M, Zagarella S, Popescu C, Bigby M. No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the multicenter selective lymphadenectomy trial-I final report. Br J Dermatol. 2015;172(3):566-571.
Kettlewell S, Moyes C, Bray C, Soutar D, Mackay A, Byrne D, et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ. 2006;332:1423.
Eroglu Z, Broman KK, Thompson JF, Nijhuis A, Hieken TJ, Kottschade L, et al. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection. J Immunother Cancer. 2022;10(8):e004417.
Howell AV, Gebregziabher M, Thiers BH, Graboyes EM, Paulos CM, Wrangle JM, et al. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors. J Geriatr Oncol. 2022;13(7):1003-1010.
Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017;22(8):963-971.
Weber J, Glutsch V, Geissinger E, Haug L, Lock JF, Schneider F, et al. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease. Br J Dermatol. 2020;183(3):559-563.
Moody JA, Ali RF, Carbone AC, Singh S, Hardwicke JT. Complications of sentinel lymph node biopsy for melanoma - a systematic review of the literature. Eur J Surg Oncol. 2017;43(2):270-277.
Valentin J, Ferté T, Dorizy-Vuong V, Dousset L, Prey S, Dutriaux C, et al. Real-world survival in patients with metastatic melanoma after discontinuation of anti-PD-1 immunotherapy for objective response or adverse effects: a retrospective study. J Oncol. 2021;2021:5524685.
Arance AM, Berrocal A, Lopez-Martin JA, de la Cruz-Merino L, Soriano V, Martín Algarra S, et al. Safety of vemurafenib in patients with BRAF. Clin Transl Oncol. 2016;18(11):1147-1157.
Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, et al. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF. Eur J Cancer. 2017;79:176-184.
Fink M, Vittrup AS, Bastholt L, Svane IM, Donia M, Luczak AA, et al. Comparison of efficacy in patients with metastatic melanoma treated with ipilimumab and nivolumab who did or did not discontinue treatment due to immune-related adverse events: a real-world data study. Cancers (Basel). 2021;13(21):5550.
Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807-3814.
Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, et al. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol. 2021;7(5):744-748.
Cakala-Jakimowicz M, Kolodziej-Wojnar P, Puzianowska-Kuznicka M. Aging-related cellular, structural and functional changes in the lymph nodes: a significant component of immunosenescence? An overview. Cells. 2021;10(11):3148.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452-2459.
Giblin AV, Hayes AJ, Thomas JM. The significance of melanoma micrometastases in the sentinel lymph node. Eur J Surg Oncol. 2005;31:1103-1104.
Thorpe RB, Covington KR, Caruso HG, Quick AP, Zolochevska O, Bricca GM, et al. Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following Mohs micrographic surgery. J Am Acad Dermatol. 2022;86(4):846-853.
Johansson I, Tempel D, Dwarkasing JT, Rentroia-Pacheco B, Mattsson J, Ny L, et al. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. Eur J Surg Oncol. 2022;48(2):320-325.